Jul 29, 2025
Hansa Biopharma announces key executive appointments to support continued growth
Jun 30, 2025
Hansa Biopharma presents positive outcomes of five-year follow-up study of imlifidase in kidney transplantation at ESOT Congress 2025 in London
Jun 11, 2025
Hansa Biopharma to attend BIO International Convention
Jun 09, 2025
Hansa Biopharma to Host Science Deep Dive Virtual Investor Event on Guillain-Barré Syndrome on June 16, 2025
Apr 24, 2025
Hansa Biopharma Reports First Quarter and Interim January-March 2025 Financial Results
Mar 21, 2025
Hansa Biopharma publishes 2024 Annual and Sustainability Reports
Jan 07, 2025
Hansa Biopharma to attend 2025 J.P. Morgan Healthcare Conference
Dec 03, 2024
Genethon and Hansa Biopharma announce initiation of a Phase 2 trial of imlifidase as a pre-treatment to GNT-0003 in severe Crigler-Najjar syndrome
Sep 05, 2024
Hansa Biopharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
Aug 23, 2024
Hansa Biopharma Announces Departure of Chief Commercial Officer, Matthew Shaulis
Jul 18, 2024
Hansa Biopharma Reports Second Quarter 2024 Financial Results and Business Update
Jul 03, 2024
Hansa Biopharma to host Q2 2024 interim results conference call
Jun 28, 2024
Hansa Biopharma: increase in number of shares and votes
Apr 18, 2024
Hansa Biopharma interim report January-March 2024
Apr 02, 2024
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance
Feb 22, 2024
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer
Feb 02, 2024
Hansa Biopharma Year-end report January-December 2023
Jan 06, 2024
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference
Feb 04, 2021
Hansa Biopharma year-end report Jan-Dec 2020
Jan 27, 2021
Hansa Biopharma to host conference call to provide Year-End report 2020 and Business Update